Cushing's Disease (DBCOND0036443)

Identifiers

Synonyms

Cushing Disease / Cushing's disease / Pituitary-dependent Cushing's disease / Pituitary-dependent Cushing's disease (disorder) / Pituitary ACTH Hypersecretion / Pituitary-dependent Cushing's syndrome

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Osilodrostat	An oral inhibitor of cortisol synthesis used to treat Cushing's disease by normalizing hypercortisolism.	Cytochrome P450 11B1, mitochondrialtarget Cytochrome P450 11B2, mitochondrialtarget Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2D6enzyme UDP-glucuronosyltransferase 1A4enzyme UDP-glucuronosyltransferase 2B7enzyme UDP-glucuronosyltransferase 2B10enzyme Cytochrome P450 3A5enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2E1enzyme Solute carrier organic anion transporter family member 1B1transporter Solute carrier family 22 member 1transporter Solute carrier family 22 member 2transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 1transporter UDP-glucuronosyltransferase 1A1enzyme
Pasireotide	A somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate.	Somatostatin receptor type 1target Somatostatin receptor type 2target Somatostatin receptor type 3target Somatostatin receptor type 5target Cytochrome P450 3A4enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02310269	Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease	Pasireotide	Not Available	Not Available	completed
NCT01504399	Rhinological Outcomes in Endonasal Pituitary Surgery	No drug interventions	Not Available	Not Available	completed
NCT02160730	Treatment of Cushing's Disease With R-roscovitine	Seliciclib	treatment	2	terminated
NCT01915303	Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease	Cabergoline Pasireotide	treatment	2	terminated
NCT02180217	Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease	Osilodrostat	treatment	3	completed
NCT01331239	Safety and Efficacy of LCI699 in Cushing's Disease Patients	Osilodrostat	treatment	2	completed
NCT00001595	An Investigation of Pituitary Tumors and Related Hypothalmic Disorders	No drug interventions	Not Available	Not Available	recruiting
NCT03831958	Long-Term Follow-Up of Survivors of Pediatric Cushing Disease	No drug interventions	Not Available	Not Available	recruiting
NCT00171951	Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease	Pasireotide	treatment	2	completed
NCT04486859	Postoperative Thrombosis Prevention in Patients With CD	Rivaroxaban	prevention	Not Available	unknown_status
NCT02233335	The Factors Associated With the Recurrence in Patients With Cushing Disease	No drug interventions	Not Available	Not Available	completed
NCT03974789	Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms	No drug interventions	Not Available	Not Available	recruiting
NCT03297892	Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015	No drug interventions	Not Available	Not Available	unknown_status
NCT04201444	Hair Cortisol and Cushing's Disease	No drug interventions	diagnostic	Not Available	completed
NCT05804669	A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	No drug interventions	treatment	1 / 2	recruiting
NCT03364803	Collecting Information About Treatment Results for Patients With Cushing's Syndrome	No drug interventions	Not Available	Not Available	recruiting
NCT04374721	Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders	No drug interventions	other	Not Available	recruiting
NCT02350153	Cushing´s Disease Epidemiology in Sweden	No drug interventions	Not Available	Not Available	completed
NCT05971758	Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease	Fimepinostat	treatment	2	not_yet_recruiting
NCT03621280	Open-label Treatment in Cushing's Syndrome	Levoketoconazole	treatment	3	completed
NCT03774446	Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	Seliciclib	treatment	2	recruiting
NCT03080181	Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment	Pasireotide	treatment	4	completed
NCT04339751	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	Vorinostat	treatment	2	recruiting
NCT04569591	Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease	Corticorelin ovine triflutate	diagnostic	Not Available	not_yet_recruiting
NCT01794793	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Cabergoline Pasireotide	treatment	4	completed
NCT03346954	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	No drug interventions	diagnostic	Not Available	completed
NCT00845351	Preoperative Bexarotene Treatment for Cushing's Disease	Bexarotene	Not Available	1 / 2	unknown_status
NCT01582061	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Pasireotide	treatment	3	completed
NCT03708900	Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease	Osilodrostat	treatment	2	recruiting
NCT00889525	Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor	Cabergoline	treatment	3	completed
NCT00434148	Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Pasireotide	treatment	3	completed
NCT06471829	A Trial of Lu AG13909 in Adult Participants With Cushing's Disease	No drug interventions	treatment	2	recruiting
NCT01925092	Mifepristone in Children With Refractory Cushing's Disease	Mifepristone	treatment	3	withdrawn
NCT03474601	Seoul National University Pituitary Disease Cohort Study	No drug interventions	Not Available	Not Available	recruiting
NCT02603653	Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease	No drug interventions	diagnostic	Not Available	unknown_status
NCT00881283	Long-term Cardiovascular Risk in Cured Cushing's Patients	No drug interventions	Not Available	Not Available	terminated
NCT02060383	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Insulin human Liraglutide Metformin Pasireotide Sitagliptin	supportive_care	4	completed
NCT01374906	Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Pasireotide	treatment	3	completed
NCT02697734	Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease	Osilodrostat	treatment	3	completed
NCT00612066	Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)	Rosiglitazone	treatment	2	terminated
NCT01371565	Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Mifepristone	treatment	3	completed
NCT02568982	Cushing's Disease Complications	No drug interventions	Not Available	Not Available	completed
NCT02484755	Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Gefitinib	treatment	2	unknown_status